Compare WHD & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHD | ARQT |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | 2018 | 2020 |
| Metric | WHD | ARQT |
|---|---|---|
| Price | $49.06 | $24.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $56.33 | $31.86 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-29-2026 | 05-25-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | 18.99 | ★ 88.79 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,079,051,000.00 | $376,072,000.00 |
| Revenue This Year | $42.81 | $34.46 |
| Revenue Next Year | $4.93 | $29.77 |
| P/E Ratio | $263.16 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $33.30 | $11.86 |
| 52 Week High | $59.25 | $31.77 |
| Indicator | WHD | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 43.36 |
| Support Level | $39.11 | $22.26 |
| Resistance Level | $59.02 | $27.65 |
| Average True Range (ATR) | 2.62 | 1.54 |
| MACD | -0.90 | -0.18 |
| Stochastic Oscillator | 0.47 | 29.08 |
Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. It has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.